Technical Data Sheet
Semaglutide
Also Known As: NN9535, Semaglutide peptide, GLP-1 agonist semaglutide, Novo Nordisk GLP-1, Semaglutide injection, Semaglutide oral, GLP-1 weight loss drug, Weight loss injection semaglutide, Diabetes GLP-1 semaglutide, Semglutide, Semagluide, Semaglutade, Ozempic shot, Wegovy injection, once-weekly GLP-1, GLP-1, GLP1, sema
Scan To View Profile
| Evidence Tier | Approved Drug |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | GLP-1 receptor agonist; fatty-acid conjugated 31-amino-acid peptide analog of human GLP-1 |
| Molecular Target | GLP-1 receptor (GLP1R); cAMP/PKA signaling; pancreatic beta-cell insulin secretion; hypothalamic appetite suppression; gastric emptying delay |
| Sequence | 31-aa GLP-1 analog (Aib2, C18 diacid) |
| Molecular Weight | ~4114 g/mol |
| CAS | 910463-68-2 |
| Parent | Human GLP-1 |
| Mechanism | It is a GLP-1 receptor agonist that slows gastric emptying and sends strong satiety signals to the hypothalamus, drastically reducing caloric intake and managing insulin release. |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Cardiovascular risk reduction, HbA1c lowering, Appetite suppression, Body weight reduction, Non-alcoholic fatty liver disease (NAFLD/MASH), Kidney disease in diabetes (SELECT trial), Obstructive sleep apnea, Alzheimer's / neurodegeneration research, Addiction / substance use disorder research, Cardiovascular outcomes improvement, Insulin resistance, Metabolic syndrome, Pre-diabetes prevention, Polycystic ovary syndrome (PCOS) research, GLP-1 receptor agonist research, weight loss, fat loss, appetite suppressant, incretin, anti-obesity, diabetes, blood sugar control, cardiovascular health, binge eating, craving reduction |
| Administration Route | Injection Only |
| Form | lyophilized (research) or pen |
| Diluent | bacteriostatic water |
| Storage Temperature | refrigerate 36-46°F pre-use |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Heat, freeze-thaw, and agitation sensitive. |
| Regulatory | FDA-approved: Ozempic (T2D, 2017); Rybelsus (oral T2D, 2019); Wegovy (obesity, 2021); Ozempic label expanded for CKD risk reduction in T2D (Jan 2025); Wegovy approved for MASH with moderate-to-advanced fibrosis (Aug 2025); Wegovy pill (oral semaglutide 25 mg) approved for chronic weight management and major adverse cardiovascular event risk reduction, US availability from January 2026 -- the first oral GLP-1 receptor agonist approved for weight management. Compounded salt forms (sodium/acetate) cautioned by FDA as not established safe/effective. Not on the WADA 2026 Prohibited List; semaglutide has been on the WADA Monitoring Program since 2024 (monitored, not sanctioned). |
| Sources |